NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

抗病毒藥物聯合治療的全球市場 - 產業分析,市場規模,佔有率,成長率,趨勢,預測:2020年∼2030年

Antiviral Combination Therapies Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020-2030

出版商 Transparency Market Research 商品編碼 969399
出版日期 內容資訊 英文 231 Pages
商品交期: 最快1-2個工作天內
價格
抗病毒藥物聯合治療的全球市場 - 產業分析,市場規模,佔有率,成長率,趨勢,預測:2020年∼2030年 Antiviral Combination Therapies Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020-2030
出版日期: 2020年10月12日內容資訊: 英文 231 Pages
簡介

本報告提供全球抗病毒藥物聯合治療市場相關調查分析,市場概要,市場規模與預測,各市場區隔的市場分析,各地區的市場分析,競爭情形相關的系統性資訊。

目錄

第1章 序文

第2章 前提條件與調查手法

第3章 摘要整理:全球抗病毒藥物聯合治療市場

第4章 市場概要

  • 定義
  • 市場指標
  • 市場動態
    • 促進因素
    • 阻礙因素
    • 機會
  • 全球市場金額預測
  • 全球市場預測

第5章 主要考察

  • COVID-19大流行對產業的影響
  • 主要的銷售藥
  • 聯合治療的專利資訊
  • 開發平台分析
  • 主要的產業活動
  • 疾病的流行病學

第6章 全球抗病毒藥物聯合治療市場分析與預測:藥物的各種組合

  • 簡介
  • 全球市場金額佔有率分析:藥物的各種組合
  • 全球市場金額預測:藥物的各種組合
    • NRTI/NNRTI
    • Integrase抑制劑/NRTI
    • NRTI
    • NRTI/蛋白分解酵素抑制劑
    • 其他
  • 全球市場魅力分析:藥物的各種組合

第7章 全球抗病毒藥物聯合治療市場分析與預測:各類型

  • 簡介
  • 全球市場金額佔有率分析:各類型
  • 全球市場金額預測:各類型
    • 品牌醫藥品
    • 學名藥
  • 全球市場魅力分析:各類型

第8章 全球抗病毒藥物聯合治療市場分析與預測:各適應症

  • 簡介
  • 全球市場金額佔有率分析:各適應症
  • 全球市場金額預測:各適應症
    • HIV
    • 肝炎
    • 其他
  • 全球市場魅力分析:各適應症

第9章 全球抗病毒藥物聯合治療市場分析與預測:各給藥途徑

  • 簡介
  • 全球市場金額佔有率分析:各給藥途徑
  • 全球市場金額預測:各給藥途徑
    • 口服
    • 靜脈內
  • 全球市場魅力分析:各給藥途徑

第10章 全球抗病毒藥物聯合治療市場分析與預測:各流通管道

  • 簡介
  • 全球市場金額佔有率分析:各流通管道
  • 全球市場金額預測:各流通管道
    • 醫院藥局
    • 零售藥局
    • 其他
  • 全球市場魅力分析:各流通管道

第11章 全球抗病毒藥物聯合治療市場分析與預測:各地區

  • 地區預測
  • 簡介
  • 全球市場金額預測:各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 南美
    • 中東、非洲
  • 全球市場魅力分析:各地區

第12章 北美的抗病毒藥物聯合治療市場分析與預測

第13章 歐洲的抗病毒藥物聯合治療市場分析與預測

第14章 亞太地區的抗病毒藥物聯合治療市場分析與預測

第15章 南美的抗病毒藥物聯合治療市場分析與預測

第16章 中東、非洲的抗病毒藥物聯合治療市場分析與預測

第17章 競爭情形

  • 市場企業:競爭矩陣
  • 市場佔有率分析:各企業
  • 企業簡介
    • Celltrion, Inc.
    • GlaxoSmithKline plc
    • Gilead Sciences, Inc.
    • AbbVie, Inc.
    • Bristol-Myers Squibb Company
    • Janssen Global Services, LLC (Pharmaceutical Companies of Johnson & Johnson)
    • Cipla, Inc.
    • Mylan NV
    • Merck & Co., Inc.
    • F. Hoffmann-La Roche Ltd.
目錄
Product Code: TMRGL76997

Title:
Antiviral Combination Therapies Market (Drug Combination: NRTI/NNRTI, Integrase Inhibitor/NRTI, NRTI, NRTI/Protease Inhibitor, and Others; Type: Branded and Generic; Indication: HIV, Hepatitis, and Others; Route of Administration: Oral and Intravenous; and Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020-2030.

Antiviral Combination Therapies Market - Scope of the Report

TMR's report on the global antiviral combination therapies market studies the past as well as current growth trends and opportunities to gain valuable insights of these indicators for the market during the forecast period from 2020 to 2030. The report provides the overall revenue of the global antiviral combination therapies market from 2018 to 2030, considering 2019 as the base year and 2030 as the forecast year. The report also provides the compound annual growth rate (CAGR) for the global antiviral combination therapies market for the forecast period.

The report has been prepared after an extensive research. Primary research involved bulk of research efforts, wherein analysts carried out interviews with market leaders and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the global antiviral combination therapies market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts also employed a combination of top-down and bottom-up approaches to study various phenomena in the global antiviral combination therapies market.

The report includes an elaborate executive summary, along with a snapshot of the growth pattern of various segments and sub-segments included in the scope of the study. Additionally, the report sheds light on the changing competition dynamics in the global antiviral combination therapies market. These indices serve as valuable tools for existing market players as well as for entities interested in participating in the global antiviral combination therapies market. The next section of the report highlights the USPs, which include major selling antiviral combination drugs, patent information of combination therapies pipeline analysis, key industry events, disease epidemiology, and COVID-19 pandemic impact on industry (value chain and short/mid/long term impact) in the global antiviral combination therapies market.

The report delves into the competition landscape of the global antiviral combination therapies market. Key players operating in the global antiviral combination therapies market have been identified and each one of these has been profiled for its distinguishing business attributes. Company overview, financial standings, recent developments, and SWOT are some of the attributes of players profiled in the global antiviral combination therapies market report.

Key Questions Answered in Antiviral Combination Therapies Market Report

What will be the sales revenue generated by antiviral combination therapies across all regions during the forecast period?

What are the key trends in the global antiviral combination therapies market?

What are major drivers, restraints, and opportunities in the global antiviral combination therapies market?

Which regional market is set to expand at the fastest CAGR during the forecast period?

Which indication segment will generate the maximum revenue by 2030 and which product segment will expand at the fastest CAGR during the forecast period?

Antiviral Combination Therapies Market - Research Objectives and Research Approach

The comprehensive report on the global antiviral combination therapies market begins with an overview of the market, followed by the scope and objectives of the study. Following this, the report provides detailed explanation of the objectives of the study and healthcare compliances laid down by accredited agencies in the purview of research in the global antiviral combination therapies market. It is followed by market introduction, market dynamics, and an overview of the global antiviral combination therapies market, which includes TMR's analysis of market drivers, restraints, and trends affecting the market. Furthermore, the Y-o-Y growth analysis with elaborate insights has been provided to understand the Y-o-Y growth trends of the global market.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller sections. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed in the entire compilation. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of market shares of key segments in the past and at the end of the forecast period.

Revenue generated by key players in the global antiviral combination therapies market has been mapped to ascertain the size of the market in terms of value. The forecast presented here assesses the total revenue generated in the global antiviral combination therapies market. In order to provide an accurate forecast, we initiated by sizing up the current antiviral combination therapies market with the help of the parent market.

The report analyzes the global antiviral combination therapies market in terms of drug combination, type, indication, route of administration, distribution channel, and region. Key segments under each criteria have been studied at length and the market share of each of these by the end of 2030 has been provided. These valuable insights would help stakeholders in making informed business decisions for investments in the global antiviral combination therapies market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Antiviral Combination Therapies Market

4. Market Overview

  • 4.1. Definition
  • 4.2. Market Indicators
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Antiviral Combination Therapies Market Value (US$ Mn) Forecast, 2018-2030
  • 4.5. Global Antiviral Combination Therapies Market Outlook

5. Key Insights

  • 5.1. COVID-19 Pandemics Impact on Industry (Value Chain and Short / Mid / Long Term Impact)
  • 5.2. Major Selling Antiviral Combination Drugs
  • 5.3. Patent Information of Combination Therapies
  • 5.4. Pipeline Analysis
  • 5.5. Key Industry Events
  • 5.6. Disease Epidemiology

6. Global Antiviral Combination Therapies Market Analysis and Forecast, by Drug Combination

  • 6.1. Introduction
  • 6.2. Global Antiviral Combination Therapies Market Value Share Analysis, by Drug Combination
  • 6.3. Global Antiviral Combination Therapies Market Value Forecast, by Drug Combination, 2018-2030
    • 6.3.1. NRTI/NNRTI
    • 6.3.2. Integrase Inhibitor/NRTI
    • 6.3.3. NRTI
    • 6.3.4. NRTI/Protease Inhibitor
    • 6.3.5. Others
  • 6.4. Global Antiviral Combination Therapies Market Attractiveness Analysis, by Drug Combination

7. Global Antiviral Combination Therapies Market Analysis and Forecast, by Type

  • 7.1. Introduction
  • 7.2. Global Antiviral Combination Therapies Market Value Share Analysis, by Type
  • 7.3. Global Antiviral Combination Therapies Market Value Forecast, by Type, 2018-2030
    • 7.3.1. Branded
    • 7.3.2. Generic
  • 7.4. Global Antiviral Combination Therapies Market Attractiveness Analysis, by Type

8. Global Antiviral Combination Therapies Market Analysis and Forecast, by Indication

  • 8.1. Introduction
  • 8.2. Global Antiviral Combination Therapies Market Value Share Analysis, by Indication
  • 8.3. Global Antiviral Combination Therapies Market Value Forecast, by Indication, 2018-2030
    • 8.3.1. HIV
    • 8.3.2. Hepatitis
    • 8.3.3. Others
  • 8.4. Global Antiviral Combination Therapies Market Attractiveness Analysis, by Indication

9. Global Antiviral Combination Therapies Market Analysis and Forecast, by Route of Administration

  • 9.1. Introduction
  • 9.2. Global Antiviral Combination Therapies Market Value Share Analysis, by Route of Administration
  • 9.3. Global Antiviral Combination Therapies Market Value Forecast, by Route of Administration, 2018-2030
    • 9.3.1. Oral
    • 9.3.2. Intravenous
  • 9.4. Global Antiviral Combination Therapies Market Attractiveness Analysis, by Route of Administration

10. Global Antiviral Combination Therapies Market Analysis and Forecast, by Distribution Channel

  • 10.1. Introduction
  • 10.2. Global Antiviral Combination Therapies Market Value Share Analysis, by Distribution Channel
  • 10.3. Global Antiviral Combination Therapies Market Value Forecast, by Distribution Channel, 2018-2030
    • 10.3.1. Hospital Pharmacies
    • 10.3.2. Retail Pharmacies
    • 10.3.3. Others
  • 10.4. Global Antiviral Combination Therapies Market Attractiveness Analysis, by Distribution Channel

11. Global Antiviral Combination Therapies Market Analysis and Forecast, by Region

  • 11.1. Regional Outlook
  • 11.2. Introduction
  • 11.3. Global Antiviral Combination Therapies Market Value Forecast, by Region
    • 11.3.1. North America
    • 11.3.2. Europe
    • 11.3.3. Asia Pacific
    • 11.3.4. Latin America
    • 11.3.5. Middle East & Africa
  • 11.4. Global Antiviral Combination Therapies Market Attractiveness Analysis, by Region

12. North America Antiviral Combination Therapies Market Analysis and Forecast

  • 12.1. Key Findings
  • 12.2. North America Antiviral Combination Therapies Market Value Forecast, by Drug Combination, 2018-2030
    • 12.2.1. NRTI/NNRTI
    • 12.2.2. Integrase Inhibitor/NRTI
    • 12.2.3. NRTI
    • 12.2.4. NRTI/Protease Inhibitor
    • 12.2.5. Others
  • 12.3. North America Antiviral Combination Therapies Market Value Forecast, by Type, 2018-2030
    • 12.3.1. Branded
    • 12.3.2. Generic
  • 12.4. North America Antiviral Combination Therapies Market Value Forecast, by Indication, 2018-2030
    • 12.4.1. HIV
    • 12.4.2. Hepatitis
    • 12.4.3. Others
  • 12.5. North America Antiviral Combination Therapies Market Value Forecast, by Route of Administration, 2018-2030
    • 12.5.1. Oral
    • 12.5.2. Intravenous
  • 12.6. North America Antiviral Combination Therapies Market Value Forecast, by Distribution Channel, 2018-2030
    • 12.6.1. Hospital Pharmacies
    • 12.6.2. Retail Pharmacies
    • 12.6.3. Others
  • 12.7. North America Antiviral Combination Therapies Market Value Forecast, by Country, 2018-2030
    • 12.7.1. U.S.
    • 12.7.2. Canada
  • 12.8. North America Antiviral Combination Therapies Attractiveness Analysis
    • 12.8.1. By Drug Combination
    • 12.8.2. By Type
    • 12.8.3. By Indication
    • 12.8.4. By Route of Administration
    • 12.8.5. By Distribution Channel
    • 12.8.6. By Country

13. Europe Antiviral Combination Therapies Market Analysis and Forecast

  • 13.1. Key Findings
  • 13.2. Europe Antiviral Combination Therapies Market Value Forecast, by Drug Combination, 2018-2030
    • 13.2.1. NRTI/NNRTI
    • 13.2.2. Integrase Inhibitor/NRTI
    • 13.2.3. NRTI
    • 13.2.4. NRTI/Protease Inhibitor
    • 13.2.5. Others
  • 13.3. Europe Antiviral Combination Therapies Market Value Forecast, by Type, 2018-2030
    • 13.3.1. Branded
    • 13.3.2. Generic
  • 13.4. Europe Antiviral Combination Therapies Market Value Forecast, by Indication, 2018-2030
    • 13.4.1. HIV
    • 13.4.2. Hepatitis
    • 13.4.3. Others
  • 13.5. Europe Antiviral Combination Therapies Market Value Forecast, by Route of Administration, 2018-2030
    • 13.5.1. Oral
    • 13.5.2. Intravenous
  • 13.6. Europe Antiviral Combination Therapies Market Value Forecast, by Distribution Channel, 2018-2030
    • 13.6.1. Hospital Pharmacies
    • 13.6.2. Retail Pharmacies
    • 13.6.3. Others
  • 13.7. Europe Antiviral Combination Therapies Market Value Forecast, by Country/Sub-region, 2018-2030
    • 13.7.1. U.K.
    • 13.7.2. Germany
    • 13.7.3. France
    • 13.7.4. Italy
    • 13.7.5. Spain
    • 13.7.6. Rest of Europe
  • 13.8. Europe Antiviral Combination Therapies Market Attractiveness Analysis
    • 13.8.1. By Drug Combination
    • 13.8.2. By Type
    • 13.8.3. By Indication
    • 13.8.4. By Route of Administration
    • 13.8.5. By Distribution Channel
    • 13.8.6. By Country/Sub-region

14. Asia Pacific Antiviral Combination Therapies Market Analysis and Forecast

  • 14.1. Key Findings
  • 14.2. Asia Pacific Antiviral Combination Therapies Market Value Forecast, by Drug Combination, 2018-2030
    • 14.2.1. NRTI/NNRTI
    • 14.2.2. Integrase Inhibitor/NRTI
    • 14.2.3. NRTI
    • 14.2.4. NRTI/Protease Inhibitor
    • 14.2.5. Others
  • 14.3. Asia Pacific Antiviral Combination Therapies Market Value Forecast, by Type, 2018-2030
    • 14.3.1. Branded
    • 14.3.2. Generic
  • 14.4. Asia Pacific Antiviral Combination Therapies Market Value Forecast, by Indication, 2018-2030
    • 14.4.1. HIV
    • 14.4.2. Hepatitis
    • 14.4.3. Others
  • 14.5. Asia Pacific Antiviral Combination Therapies Market Value Forecast, by Route of Administration, 2018-2030
    • 14.5.1. Oral
    • 14.5.2. Intravenous
  • 14.6. Asia Pacific Antiviral Combination Therapies Market Value Forecast, by Distribution Channel, 2018-2030
    • 14.6.1. Hospital Pharmacies
    • 14.6.2. Retail Pharmacies
    • 14.6.3. Others
  • 14.7. Asia Pacific Antiviral Combination Therapies Market Value Forecast, by Country/Sub-region, 2018-2030
    • 14.7.1. China
    • 14.7.2. India
    • 14.7.3. Japan
    • 14.7.4. Australia & New Zealand
    • 14.7.5. Rest of Asia Pacific
  • 14.8. Asia Pacific Antiviral Combination Therapies Market Attractiveness Analysis
    • 14.8.1. By Drug Combination
    • 14.8.2. By Type
    • 14.8.3. By Indication
    • 14.8.4. By Route of Administration
    • 14.8.5. By Distribution Channel
    • 14.8.6. By Country/Sub-region

15. Latin America Antiviral Combination Therapies Market Analysis and Forecast

  • 15.1. Key Findings
  • 15.2. Latin America Antiviral Combination Therapies Market Value Forecast, by Drug Combination, 2018-2030
    • 15.2.1. NRTI/NNRTI
    • 15.2.2. Integrase Inhibitor/NRTI
    • 15.2.3. NRTI
    • 15.2.4. NRTI/Protease Inhibitor
    • 15.2.5. Others
  • 15.3. Latin America Antiviral Combination Therapies Market Value Forecast, by Type, 2018-2030
    • 15.3.1. Branded
    • 15.3.2. Generic
  • 15.4. Latin America Antiviral Combination Therapies Market Value Forecast, by Indication, 2018-2030
    • 15.4.1. HIV
    • 15.4.2. Hepatitis
    • 15.4.3. Others
  • 15.5. Latin America Antiviral Combination Therapies Market Value Forecast, by Route of Administration, 2018-2030
    • 15.5.1. Oral
    • 15.5.2. Intravenous
  • 15.6. Latin America Antiviral Combination Therapies Market Value Forecast, by Distribution Channel, 2018-2030
    • 15.6.1. Hospital Pharmacies
    • 15.6.2. Retail Pharmacies
    • 15.6.3. Others
  • 15.7. Latin America Antiviral Combination Therapies Market Value Forecast, by Country/Sub-region, 2018-2030
    • 15.7.1. Brazil
    • 15.7.2. Mexico
    • 15.7.3. Rest of Latin America
  • 15.8. Latin America Antiviral Combination Therapies Market Attractiveness Analysis
    • 15.8.1. By Drug Combination
    • 15.8.2. By Type
    • 15.8.3. By Indication
    • 15.8.4. By Route of Administration
    • 15.8.5. By Distribution Channel
    • 15.8.6. By Country/Sub-region

16. Middle East & Africa Antiviral Combination Therapies Market Analysis and Forecast

  • 16.1. Key Findings
  • 16.2. Middle East & Africa Antiviral Combination Therapies Market Value Forecast, by Drug Combination, 2018-2030
    • 16.2.1. NRTI/NNRTI
    • 16.2.2. Integrase Inhibitor/NRTI
    • 16.2.3. NRTI
    • 16.2.4. NRTI/Protease Inhibitor
    • 16.2.5. Others
  • 16.3. Middle East & Africa Antiviral Combination Therapies Market Value Forecast, by Type, 2018-2030
    • 16.3.1. Branded
    • 16.3.2. Generic
  • 16.4. Middle East & Africa Antiviral Combination Therapies Market Value Forecast, by Indication, 2018-2030
    • 16.4.1. HIV
    • 16.4.2. Hepatitis
    • 16.4.3. Others
  • 16.5. Middle East & Africa Antiviral Combination Therapies Market Value Forecast, by Route of Administration, 2018-2030
    • 16.5.1. Oral
    • 16.5.2. Intravenous
  • 16.6. Middle East & Africa Antiviral Combination Therapies Market Value Forecast, by Distribution Channel, 2018-2030
    • 16.6.1. Hospital Pharmacies
    • 16.6.2. Retail Pharmacies
    • 16.6.3. Others
  • 16.7. Middle East & Africa Antiviral Combination Therapies Market Value Forecast, by Country/Sub-region, 2018-2030
    • 16.7.1. GCC Countries
    • 16.7.2. South Africa
    • 16.7.3. Rest of Middle East & Africa
  • 16.8. Middle East & Africa Antiviral Combination Therapies Market Attractiveness Analysis
    • 16.8.1. By Drug Combination
    • 16.8.2. By Type
    • 16.8.3. By Indication
    • 16.8.4. By Route of Administration
    • 16.8.5. By Distribution Channel
    • 16.8.6. By Country/Sub-region

17. Competition Landscape

  • 17.1. Market Player - Competition Matrix (by tier and size of companies)
  • 17.2. Market Share Analysis, by Company, 2019
  • 17.3. Company Profiles
    • 17.3.1. Celltrion, Inc.
      • 17.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 17.3.1.2. Financial Overview
      • 17.3.1.3. Product Portfolio
      • 17.3.1.4. Strategic Overview
      • 17.3.1.5. SWOT Analysis
    • 17.3.2. GlaxoSmithKline plc
      • 17.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 17.3.2.2. Financial Overview
      • 17.3.2.3. Product Portfolio
      • 17.3.2.4. Strategic Overview
      • 17.3.2.5. SWOT Analysis
    • 17.3.3. Gilead Sciences, Inc.
      • 17.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 17.3.3.2. Financial Overview
      • 17.3.3.3. Product Portfolio
      • 17.3.3.4. Strategic Overview
      • 17.3.3.5. SWOT Analysis
    • 17.3.4. AbbVie, Inc.
      • 17.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 17.3.4.2. Financial Overview
      • 17.3.4.3. Product Portfolio
      • 17.3.4.4. Strategic Overview
      • 17.3.4.5. SWOT Analysis
    • 17.3.5. Bristol-Myers Squibb Company
      • 17.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 17.3.5.2. Financial Overview
      • 17.3.5.3. Product Portfolio
      • 17.3.5.4. Strategic Overview
      • 17.3.5.5. SWOT Analysis
    • 17.3.6. Janssen Global Services, LLC (Pharmaceutical Companies of Johnson & Johnson)
      • 17.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 17.3.6.2. Financial Overview
      • 17.3.6.3. Product Portfolio
      • 17.3.6.4. Strategic Overview
      • 17.3.6.5. SWOT Analysis
    • 17.3.7. Cipla, Inc.
      • 17.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 17.3.7.2. Financial Overview
      • 17.3.7.3. Product Portfolio
      • 17.3.7.4. Strategic Overview
      • 17.3.7.5. SWOT Analysis
    • 17.3.8. Mylan N.V.
      • 17.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 17.3.8.2. Financial Overview
      • 17.3.8.3. Product Portfolio
      • 17.3.8.4. Strategic Overview
      • 17.3.8.5. SWOT Analysis
    • 17.3.9. Merck & Co., Inc.
      • 17.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 17.3.9.2. Financial Overview
      • 17.3.9.3. Product Portfolio
      • 17.3.9.4. Strategic Overview
      • 17.3.9.5. SWOT Analysis
    • 17.3.10. F. Hoffmann-La Roche Ltd.
      • 17.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 17.3.10.2. Financial Overview
      • 17.3.10.3. Product Portfolio
      • 17.3.10.4. Strategic Overview
      • 17.3.10.5. SWOT Analysis

List of Tables

  • Table 01: Global Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Drug Combination, 2018-2030
  • Table 02: Global Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Type, 2018-2030
  • Table 03: Global Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Indication, 2018-2030
  • Table 04: Global Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Route of Administration, 2018-2030
  • Table 05: Global Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Distribution Channel, 2018-2030
  • Table 06: Global Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Region, 2018-2030
  • Table 07: North America Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Country, 2018-2030
  • Table 08: North America Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Drug Combination, 2018-2030
  • Table 09: North America Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Type, 2018-2030
  • Table 10: North America Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Indication, 2018-2030
  • Table 11: North America Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Route of Administration, 2018-2030
  • Table 12: North America Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Distribution Channel, 2018-2030
  • Table 13: Europe Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018-2030
  • Table 14: Europe Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Drug Combination, 2018-2030
  • Table 15: Europe Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Type, 2018-2030
  • Table 16: Europe Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Indication, 2018-2030
  • Table 17: Europe Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Route of Administration, 2018-2030
  • Table 18: Europe Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Distribution Channel, 2018-2030
  • Table 19: Asia Pacific Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018-2030
  • Table 20: Asia Pacific Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Drug Combination, 2018-2030
  • Table 21: Asia Pacific Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Type, 2018-2030
  • Table 22: Asia Pacific Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Indication, 2018-2030
  • Table 23: Asia Pacific Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Route of Administration, 2018-2030
  • Table 24: Asia Pacific Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Distribution Channel, 2018-2030
  • Table 25: Latin America Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018-2030
  • Table 26: Latin America Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Drug Combination, 2018-2030
  • Table 27: Latin America Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Type, 2018-2030
  • Table 28: Latin America Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Indication, 2018-2030
  • Table 29: Latin America Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Route of Administration, 2018-2030
  • Table 30: Latin America Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Distribution Channel, 2018-2030
  • Table 31: Middle East & Africa Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Country/Sub-region, 2018-2030
  • Table 32: Middle East & Africa Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Drug Combination, 2018-2030
  • Table 33: Middle East & Africa Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Type, 2018-2030
  • Table 34: Middle East & Africa Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Indication, 2018-2030
  • Table 35: Middle East & Africa Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Route of Administration, 2018-2030
  • Table 36: Middle East & Africa Antiviral Combination Therapies Market Value (US$ Mn) Forecast, by Distribution Channel, 2018-2030

List of Figures

  • Figure 01: Global Antiviral Combination Therapies Market Value (US$ Mn) Forecast, 2018-2030
  • Figure 02: Global Antiviral Combination Therapies Market Value Share, by Drug Combination, 2019
  • Figure 03: Global Antiviral Combination Therapies Market Value Share, by Type, 2019
  • Figure 04: Global Antiviral Combination Therapies Market Value Share, by Indication, 2019
  • Figure 05: Global Antiviral Combination Therapies Market Value Share, by Route of Administration, 2019
  • Figure 06: Global Antiviral Combination Therapies Market Value Share, by Distribution Channel, 2019
  • Figure 07: Global Antiviral Combination Therapies Market Value Share Analysis, by Drug Combination, 2019 and 2030
  • Figure 08: Global Antiviral Combination Therapies Market Attractiveness Analysis, by Drug Combination, 2020-2030
  • Figure 09: Global Antiviral Combination Therapies Market Value (US$ Mn), by NRTI/NNRTI, 2018-2030
  • Figure 10: Global Antiviral Combination Therapies Market Value (US$ Mn), by Integrase Inhibitor/NRTI, 2018-2030
  • Figure 11: Global Antiviral Combination Therapies Market Value (US$ Mn), by NRTI, 2018-2030
  • Figure 12: Global Antiviral Combination Therapies Market Value (US$ Mn), by NRTI/Protease Inhibitor, 2018-2030
  • Figure 13: Global Antiviral Combination Therapies Market Value (US$ Mn), by Others, 2018-2030
  • Figure 14: Global Antiviral Combination Therapies Market Value Share Analysis, by Type, 2019 and 2030
  • Figure 15: Global Antiviral Combination Therapies Market Attractiveness Analysis, by Type, 2020-2030
  • Figure 16: Global Antiviral Combination Therapies Market Value (US$ Mn), by Branded, 2018-2030
  • Figure 17: Global Antiviral Combination Therapies Market Value (US$ Mn), by Generic, 2018-2030
  • Figure 18: Global Antiviral Combination Therapies Market Value Share Analysis, by Indication, 2019 and 2030
  • Figure 19: Global Antiviral Combination Therapies Market Attractiveness Analysis, by Indication, 2020-2030
  • Figure 20: Global Antiviral Combination Therapies Market Value (US$ Mn), by HIV, 2018-2030
  • Figure 21: Global Antiviral Combination Therapies Market Value (US$ Mn), by Hepatitis, 2018-2030
  • Figure 22: Global Antiviral Combination Therapies Market Value (US$ Mn), by Others, 2018-2030
  • Figure 23: Global Antiviral Combination Therapies Market Value Share Analysis, by Route of Administration, 2019 and 2030
  • Figure 24: Global Antiviral Combination Therapies Market Attractiveness Analysis, by Route of Administration, 2020-2030
  • Figure 25: Global Antiviral Combination Therapies Market Value (US$ Mn), by Oral, 2018-2030
  • Figure 26: Global Antiviral Combination Therapies Market Value (US$ Mn), by Intravenous, 2018-2030
  • Figure 27: Global Antiviral Combination Therapies Market Value Share Analysis, by Distribution Channel, 2019 and 2030
  • Figure 28: Global Antiviral Combination Therapies Market Attractiveness Analysis, by Distribution Channel, 2020-2030
  • Figure 29: Global Antiviral Combination Therapies Market Value (US$ Mn), by Hospital Pharmacies, 2018-2030
  • Figure 30: Global Antiviral Combination Therapies Market Value (US$ Mn), by Retail Pharmacies, 2018-2030
  • Figure 31: Global Antiviral Combination Therapies Market Value (US$ Mn), by Others, 2018-2030
  • Figure 32: Global Antiviral Combination Therapies Market Value Share Analysis, by Region, 2019 and 2030
  • Figure 33: Global Antiviral Combination Therapies Market Attractiveness Analysis, by Region
  • Figure 34: North America Antiviral Combination Therapies Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018-2030
  • Figure 35: North America Antiviral Combination Therapies Market Value Share Analysis, by Country, 2019 and 2030
  • Figure 36: North America Antiviral Combination Therapies Market Attractiveness Analysis, by Country, 2020-2030
  • Figure 37: North America Antiviral Combination Therapies Market Value Share Analysis, by Drug Combination, 2019 and 2030
  • Figure 38: North America Antiviral Combination Therapies Market Attractiveness Analysis, by Drug Combination, 2020-2030
  • Figure 39: North America Antiviral Combination Therapies Market Value Share Analysis, by Type, 2019 and 2030
  • Figure 40: North America Antiviral Combination Therapies Market Attractiveness Analysis, by Type, 2020-2030
  • Figure 41: North America Antiviral Combination Therapies Market Value Share Analysis, by Indication, 2019 and 2030
  • Figure 42: North America Antiviral Combination Therapies Market Attractiveness Analysis, by Indication, 2020-2030
  • Figure 43: North America Antiviral Combination Therapies Market Value Share Analysis, by Route of Administration, 2019 and 2030
  • Figure 44: North America Antiviral Combination Therapies Market Attractiveness Analysis, by Route of Administration, 2020-2030
  • Figure 45: North America Antiviral Combination Therapies Market Value Share Analysis, by Distribution Channel, 2019 and 2030
  • Figure 46: North America Antiviral Combination Therapies Market Attractiveness Analysis, by Distribution Channel, 2020-2030
  • Figure 47: Europe Antiviral Combination Therapies Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018-2030
  • Figure 48: Europe Antiviral Combination Therapies Market Value Share Analysis, by Country/Sub-region, 2019 and 2030
  • Figure 49: Europe Antiviral Combination Therapies Market Attractiveness Analysis, by Country/Sub-region, 2020-2030
  • Figure 50: Europe Antiviral Combination Therapies Market Value Share Analysis, by Drug Combination, 2019 and 2030
  • Figure 51: Europe Antiviral Combination Therapies Market Attractiveness Analysis, by Drug Combination, 2020-2030
  • Figure 52: Europe Antiviral Combination Therapies Market Value Share Analysis, by Type, 2019 and 2030
  • Figure 53: Europe Antiviral Combination Therapies Market Attractiveness Analysis, by Type, 2020-2030
  • Figure 54: Europe Antiviral Combination Therapies Market Value Share Analysis, by Indication, 2019 and 2030
  • Figure 55: Europe Antiviral Combination Therapies Market Attractiveness Analysis, by Indication, 2020-2030
  • Figure 56: Europe Antiviral Combination Therapies Market Value Share Analysis, by Route of Administration, 2019 and 2030
  • Figure 57: Europe Antiviral Combination Therapies Market Attractiveness Analysis, by Route of Administration, 2020-2030
  • Figure 58: Europe Antiviral Combination Therapies Market Value Share Analysis, by Distribution Channel, 2019 and 2030
  • Figure 59: Europe Antiviral Combination Therapies Market Attractiveness Analysis, by Distribution Channel, 2020-2030
  • Figure 60: Asia Pacific Antiviral Combination Therapies Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018-2030
  • Figure 61: Asia Pacific Antiviral Combination Therapies Market Value Share Analysis, by Country/Sub-region, 2019 and 2030
  • Figure 62: Asia Pacific Antiviral Combination Therapies Market Attractiveness Analysis, by Country/Sub-region, 2020-2030
  • Figure 63: Asia Pacific Antiviral Combination Therapies Market Value Share Analysis, by Drug Combination, 2019 and 2030
  • Figure 64: Asia Pacific Antiviral Combination Therapies Market Attractiveness Analysis, by Drug Combination, 2020-2030
  • Figure 65: Asia Pacific Antiviral Combination Therapies Market Value Share Analysis, by Type, 2019 and 2030
  • Figure 66: Asia Pacific Antiviral Combination Therapies Market Attractiveness Analysis, by Type, 2020-2030
  • Figure 67: Asia Pacific Antiviral Combination Therapies Market Value Share Analysis, by Indication, 2019 and 2030
  • Figure 68: Asia Pacific Antiviral Combination Therapies Market Attractiveness Analysis, by Indication, 2020-2030
  • Figure 69: Asia Pacific Antiviral Combination Therapies Market Value Share Analysis, by Route of Administration, 2019 and 2030
  • Figure 70: Asia Pacific Antiviral Combination Therapies Market Attractiveness Analysis, by Route of Administration, 2020-2030
  • Figure 71: Asia Pacific Antiviral Combination Therapies Market Value Share Analysis, by Distribution Channel, 2019 and 2030
  • Figure 72: Asia Pacific Antiviral Combination Therapies Market Attractiveness Analysis, by Distribution Channel, 2020-2030
  • Figure 73: Latin America Antiviral Combination Therapies Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018-2030
  • Figure 74: Latin America Antiviral Combination Therapies Market Value Share Analysis, by Country/Sub-region, 2019 and 2030
  • Figure 75: Latin America Antiviral Combination Therapies Market Attractiveness Analysis, by Country/Sub-region, 2020-2030
  • Figure 76: Latin America Antiviral Combination Therapies Market Value Share Analysis, by Drug Combination, 2019 and 2030
  • Figure 77: Latin America Antiviral Combination Therapies Market Attractiveness Analysis, by Drug Combination, 2020-2030
  • Figure 78: Latin America Antiviral Combination Therapies Market Value Share Analysis, by Type, 2019 and 2030
  • Figure 79: Latin America Antiviral Combination Therapies Market Attractiveness Analysis, by Type, 2020-2030
  • Figure 80: Latin America Antiviral Combination Therapies Market Value Share Analysis, by Indication, 2019 and 2030
  • Figure 81: Latin America Antiviral Combination Therapies Market Attractiveness Analysis, by Indication, 2020-2030
  • Figure 82: Latin America Antiviral Combination Therapies Market Value Share Analysis, by Route of Administration, 2019 and 2030
  • Figure 83: Latin America Antiviral Combination Therapies Market Attractiveness Analysis, by Route of Administration, 2020-2030
  • Figure 84: Latin America Antiviral Combination Therapies Market Value Share Analysis, by Distribution Channel, 2019 and 2030
  • Figure 85: Latin America Antiviral Combination Therapies Market Attractiveness Analysis, by Distribution Channel, 2020-2030
  • Figure 86: Middle East & Africa Antiviral Combination Therapies Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018-2030
  • Figure 87: Middle East & Africa Antiviral Combination Therapies Market Value Share Analysis, by Country/Sub-region, 2019 and 2030
  • Figure 88: Middle East & Africa Antiviral Combination Therapies Market Attractiveness Analysis, by Country/Sub-region, 2020-2030
  • Figure 89: Middle East & Africa Antiviral Combination Therapies Market Value Share Analysis, by Drug Combination, 2019 and 2030
  • Figure 90: Middle East & Africa Antiviral Combination Therapies Market Attractiveness Analysis, by Drug Combination, 2020-2030
  • Figure 91: Middle East & Africa Antiviral Combination Therapies Market Value Share Analysis, by Type, 2019 and 2030
  • Figure 92: Middle East & Africa Antiviral Combination Therapies Market Attractiveness Analysis, by Type, 2020-2030
  • Figure 93: Middle East & Africa Antiviral Combination Therapies Market Value Share Analysis, by Indication, 2019 and 2030
  • Figure 94: Middle East & Africa Antiviral Combination Therapies Market Attractiveness Analysis, by Indication, 2020-2030
  • Figure 95: Middle East & Africa Antiviral Combination Therapies Market Value Share Analysis, by Route of Administration, 2019 and 2030
  • Figure 96: Middle East & Africa Antiviral Combination Therapies Market Attractiveness Analysis, by Route of Administration, 2020-2030
  • Figure 97: Middle East & Africa Antiviral Combination Therapies Market Value Share Analysis, by Distribution Channel, 2019 and 2030
  • Figure 98: Middle East & Africa Antiviral Combination Therapies Market Attractiveness Analysis, by Distribution Channel, 2020-2030
  • Figure 99: Global Antiviral Combination Therapies Market - Company Share Analysis (2019)